Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Long-Term Investments (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Long-Term Investments for 13 consecutive years, with $20.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Long-Term Investments fell 16.53% to $20.7 million in Q4 2025 year-over-year; TTM through Oct 2025 was $20.7 million, a 16.53% decrease, with the full-year FY2025 number at $22.5 million, changed N/A from a year prior.
  • Long-Term Investments was $20.7 million for Q4 2025 at PharmaCyte Biotech, up from $19.6 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $29.1 million in Q3 2024 to a low of $1.6 million in Q1 2021.
  • A 5-year average of $8.2 million and a median of $1.6 million in 2021 define the central range for Long-Term Investments.
  • Peak YoY movement for Long-Term Investments: soared 1752.19% in 2024, then crashed 32.57% in 2025.
  • PharmaCyte Biotech's Long-Term Investments stood at $1.6 million in 2021, then changed by 0.0% to $1.6 million in 2022, then changed by 0.0% to $1.6 million in 2023, then surged by 1480.91% to $24.9 million in 2024, then dropped by 16.53% to $20.7 million in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Long-Term Investments are $20.7 million (Q4 2025), $19.6 million (Q3 2025), and $22.5 million (Q2 2025).